Overview

A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults A

Status:
COMPLETED
Trial end date:
2025-11-27
Target enrollment:
Participant gender:
Summary
Bioequivalence study for the fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg under fed conditions in healthy volunteers
Phase:
PHASE1
Details
Lead Sponsor:
LG Chem
Treatments:
dapagliflozin
Drug Evaluation
LC15-0444
Metformin